Skip to main content

Curis, Inc.

corporate_fare Company Profile

Curis, Inc.

CRIS·NASDAQ·Life Sciences·CIK 0001108205

The company is a biotechnology company focused on developing emavusertib (CA-4948), an oral, small molecule inhibitor targeting Interleukin-1 receptor associated kinase (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Emavusertib is currently being studied in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), where it is combined with ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor. It is also being evaluated in the recently started TakeAim CLL study, a Phase 2 combination study for chronic lymphocytic leukemia (CLL) with zanubrutinib, another BTK inhibitor. The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are largely complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating PCNSL, AML, and myelodysplastic syndromes (MDS), and from the European Commission for treating PCNSL. The company holds the exclusive license to emavusertib (CA-4948) through a 2015 collaboration with Aurigene Discovery Technologies Limited. As of December 31, 2025, the company had $5.1 million in cash and cash equivalents. In January 2026, it completed a private placement, the January 2026 PIPE Financing, which generated net proceeds of approximately $18.6 million.

Curis, Inc. (NASDAQ:CRIS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for CRIS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Curis Reports Q1 Net Loss of $24.2M, Zero Revenue; Projects Conditional Cash Runway into H2 2027 Amid Delisting Threat
  • Curis Reports $1.25/Share Q1 Loss Amid Delisting Concerns
  • Curis Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price
  • Curis Inc. Receives Nasdaq Delisting Notice, Plans Appeal to Avoid Suspension
  • Curis Files Definitive Proxy for Shareholder Vote on Massive 1300% Potential Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.44M
Net Income
-$7.58M
Diluted EPS
-$0.58
Op. Cash Flow
-$27.2M
Operating Income
-$5.71M
Cash & Equivalents
$5.06M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-80.3%
Shares Outstanding
12.93M sh
Source: 10-K · filed 2026-03-24 · accession 0001108205-26-000043
$0.432 +1.17% today
52-week range · as of 2026-11-13 $0.325 – $28.4
Market cap
$4.06M
Volume
531.1K (0.1× avg)
3-mo avg 9.1M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRIS - Filings & News (Page 2)

CRIS
May 12, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5504
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 12, 2026, 4:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.5465
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 01, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.592
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 01, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5881
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Apr 21, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.590
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Apr 10, 2026, 4:19 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.474
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Mar 24, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.715
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Mar 24, 2026, 5:00 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.715
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Mar 19, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7569
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Mar 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8916
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Feb 19, 2026, 4:12 PM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.14
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Feb 13, 2026, 4:21 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.18
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Feb 09, 2026, 4:55 PM EST
Filing Type: PRE 14A
Importance Score:
10
Price at Filing: $0.9688
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Feb 09, 2026, 4:53 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9688
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets